Last reviewed · How we verify
Modified FOLFIRI
At a glance
| Generic name | Modified FOLFIRI |
|---|---|
| Sponsor | AbbVie |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) (PHASE1)
- FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer (PHASE2)
- Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer (PHASE2)
- Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (PHASE1)
- Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC (PHASE2)
- Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12) (PHASE3)
- Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network (PHASE2)
- Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Modified FOLFIRI CI brief — competitive landscape report
- Modified FOLFIRI updates RSS · CI watch RSS
- AbbVie portfolio CI